The emerging field of exosome therapy has attracted considerable attention in Japan's regenerative medicine community, but clinical availability remains restricted under PMDA regulations. For Japanese patients interested in cell-free regenerative treatment using biological signalling vesicles, our clinic in Chiang Mai, approximately six hours from Tokyo or Osaka, offers exosome therapy with Japanese-speaking staff and structured follow-up with your Japanese medical team.
Exosome therapy uses cell-free extracellular vesicles to deliver regenerative signalling molecules directly to damaged tissue. As a cell-free biological, exosomes carry growth factors, RNA, and proteins that promote tissue repair without the complexity of live cell transplantation. Treatment involves targeted delivery of purified exosomes to affected areas, often combined with other regenerative modalities for enhanced outcomes. For a comprehensive understanding of the science, evidence, and treatment process, visit our full Exosome Therapy page.
The cell-free nature of exosome therapy appeals to Japanese patients who want regenerative benefits with minimal downtime and lower immunological risk compared to cell-based treatments. Treatment programmes are shorter than stem cell protocols, typically three to five days, making it practical for patients travelling from overseas. Japanese-speaking coordination, significant cost savings compared to any limited domestic options, and structured physician follow-up make the process straightforward.
Exosomes are nanoscale vesicles that carry biological signals between cells, promoting tissue repair and modulating inflammation.
Exosome therapy is cell-free, delivering only the signalling molecules rather than whole cells.
Typically three to five days in Chiang Mai.
Yes. It is frequently combined with stem cell and anti-ageing protocols.
Minimal to none. Most patients resume activities immediately.
Exosome therapy is an active area of research in Japan but clinical access remains limited under PMDA. Thailand offers regulated access under medical supervision.
PMDA classifies exosome therapies as cell therapy products requiring extensive pre-market approval. This classification places exosome treatments under the same rigorous regulatory pathway as stem cell therapies, significantly limiting their clinical availability in Japan.
Yes. The Act on the Safety of Regenerative Medicine covers exosome-based therapies in Japan, requiring institutional review and PMDA notification. This regulatory requirement limits the number of facilities that can offer exosome treatments domestically.
Yes. Our dedicated Japanese-speaking coordinator manages all aspects of your exosome therapy journey, from pre-arrival consultation through treatment and post-treatment follow-up, ensuring precise communication at every stage.